Tecentriq Data Builds As IMpower132 In NSCLC Meets PFS Co-Primary Endpoint
As Roche keeps building its catalog of positive Tecentriq results, its Phase III IMpower132 study meets PFS endpoint in NSCLC, with OS data coming later.
You may also be interested in...
The lack of significant overall survival benefit in IMpower132 may be related to PD-L1 expression – though the dataset is incomplete – or the higher dose of chemo used in the trial.
The recently launched Opdivo/Yervoy combination already has a leading position in first-line kidney cancer in the US – with a 30% share of new patients – but has been rejected in Europe.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.